Compare Neurocrine Biosciences Inc (NBIX) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NextEra Energy, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while NextEra Energy, Inc. trades at $77.35 (market cap $160.75B). The key difference: NextEra Energy, Inc. is far larger — about 11× Neurocrine Biosciences Inc's market cap, and NextEra Energy, Inc. pays a 3.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and NextEra Energy, Inc. for 83 Days on average.
| NBIX | NEE | |
|---|---|---|
Market Cap | $14.60B | $160.75B |
Volume | 1,075,694 | 10,598,021 |
Sector | Health | Utilities |
52-Week High | $185.50 | $97.88 |
52-Week Low | $123.10 | $75.49 |
Typical Hold Time | 23 Days | 83 Days |
Enterprise Value | $14.61B | $268.08B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
NextEra Energy (NEE) trades at $77.37, down 0.65% with a bearish technical signal. The stock shows strong fundamentals with 32.4% net income margin and 17.23% ROE, though recent earnings were mixed with a Q4 miss but Q1-Q2 beats. Analyst consensus remains bullish with 66.7% buy ratings and $96 price target. Recent news highlights growth opportunities including a $22.3 billion energy infrastructure partnership and 18 GW gas development prospects.
NEE presents a compelling long-term investment case with robust profitability and analyst support, though near-term technical weakness and rising debt levels warrant caution. The company's clean energy transition strategy and infrastructure projects provide growth catalysts, but interest rate sensitivity and execution risks on large projects represent key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
